SCHEMBL4090028

SCHEMBL4090028

COc1cccc2nc(-c3ccccc3Cl)nc(N3CCCC3)c12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.62
HIF1A Q16665 6/20 0.58
CYP1A2 P05177 3/20 0.51
CYP3A4 P08684 3/20 0.51
TSHR P16473 1/20 0.51
MAPT P10636 8/20 0.50
CYP2D6 P10635 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
USP2 O75604 1/20 0.50
MAPK1 P28482 1/20 0.50
CLK4 Q9HAZ1 1/20 0.50
RAD52 P43351 1/20 0.49
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090727 0.86 ABCB1 (0.73) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL4091807 0.86 MAPT (0.48) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL1084081 0.86 HIF1A (0.64) HIF1ACYP1A2CYP3A4TSHRMAPT
SCHEMBL1084035 0.85 HIF1A (0.66) HIF1ACYP1A2CYP3A4TSHRMAPT
SCHEMBL4753835 0.85 MEN1 (0.52) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL4092379 0.84 ABCB1 (0.67) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL4090616 0.83 KMT2A (0.49) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL4084544 0.82 ABCB1 (0.67) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL4090855 0.79 ABCB1 (0.62) ABCB1HIF1ACYP1A2CYP3A4TSHR
SCHEMBL1084135 0.77 ABCB1 (1.00) ABCB1HIF1ACYP1A2CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ABCB1 2120/4885HIF1A 1496/4885CYP1A2 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.